USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
O-RAY PHARMA, INC.
Address:
2285 EAST FOOTHILL BLVD
PASADENA, CA 91107-
Phone:
N/A
URL:
N/A
EIN:
126025461
DUNS:
800316361
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $154,472.00 1
SBIR Phase II $1,071,370.00 1

Award List:

Sustained Release Inner Ear Delivery of Corticosteroid

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$1,071,370.00
Agency:
HHS
Principal Investigator:
William H. Slattery
Abstract:
DESCRIPTION (provided by applicant): Project Summary The broad long term goal of this research program is to reduce or eliminate deafness by developing sustained release intracochlear drug delivery systems. The goal of this project is to develop a ster oid eluting cochlear implant. Currently,… More

Ototoxicity protection with intratympanic steroid implant

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$154,472.00
Agency:
HHS
Principal Investigator:
Erik Pierstorff – 626-844-1906
Abstract:
DESCRIPTION (provided by applicant): Chemotherapy-induced ototoxicity is damage to the inner ear that is caused by the side effects of administered drugs. This can lead to permanent hearing loss and/or tinnitus (continuous ringing in the ear) in the patient. Some of the most common kinds of drugs… More